![]() | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C10H14N5O4P |
| Molar mass | 299.227 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Besifovir (INN) is an investigational medication to treat hepatitis B virus (HBV) infection. It is a novel and potent acyclic nucleotide phosphonate with a similar chemical structure to adefovir and tenofovir.[2]
References
- ↑ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on 2008-05-06. Retrieved 2008-09-05.
- ↑ Lin CL, Yang HC, Kao JH (4 January 2016). "Hepatitis B virus: new therapeutic perspectives". Liver Int. 36 (Supplement S1): 85–92. doi:10.1111/liv.13003. PMID 26725903.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
